Budget 2017-18

---

Pre-rebate PBS spending is being distorted by the significant short-term impact of hepatitis C therapies $11.2b $10.9b

$11.02b $10.7b $10.63b

$10.8b

$10.6b

$10.29b $10.1b

2016-17

2017-18

2018-19

2016-17 Budget

2019-20

2017-18

*Source: Department of Health Portfolio Budget Statements, Special appropriations National Health Act 1953 pharmaceutical benefits

2020-21

The short-term impact of hepatitis C medicines on total spending on the pharmaceutical benefits and service sub-function will moderate over time $12.6b $12.3b

$12.2b

$12.3b $12.2b

$11.9b $11.5b

2016-17

$11.8b

$11.6b

2017-18

2018-19

2016-17 Budget *Source: Budget Paper No.1, Summary of Expenses, Health

2019-20

2017-18 Budget

2020-21

Forecast savings from price disclosure of $20 billion over the five years to 2020-21

$4.8 $4.4b $4b $3.6b $3.2b

2016-17

2017-18 2017-18

*Source: Department of Health Portfolio Budget Statements

2018-19

2019-20

2020-21